Cargando…

Risk of Recall Among Medical Devices Undergoing US Food and Drug Administration 510(k) Clearance and Premarket Approval, 2008-2017

IMPORTANCE: The US Food and Drug Administration (FDA) uses 510(k) clearance and premarket approval (PMA) pathways to ensure device safety before marketing. Premarket approval evaluates high-risk medical devices and requires clinical trials, whereas 510(k) clearance evaluates moderate-risk devices an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dubin, Jonathan R., Simon, Stephen D., Norrell, Kirsten, Perera, Jacob, Gowen, Jacob, Cil, Akin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103223/ https://www.ncbi.nlm.nih.gov/pubmed/33956132 http://dx.doi.org/10.1001/jamanetworkopen.2021.7274

Ejemplares similares

Premarket Approval Through the 510(k) Process: Lessons from the Translation Process of Magnetic Resonance Elastography
por: Aponte Ortiz, Jaime A., et al.
Publicado: (2018)

Risk of Recall Associated With Modifications to High-risk Medical Devices Approved Through US Food and Drug Administration Supplements
por: Dubin, Jonathan R., et al.
Publicado: (2023)

Quantification of US Food and Drug Administration Premarket Approval Statements for High-Risk Medical Devices With Pediatric Age Indications
por: Lee, Samuel J., et al.
Publicado: (2021)

Overview of the Premarketing and Postmarketing Requirements for Drugs Granted Japanese Conditional Marketing Approval
por: Matsushita, Shunsuke, et al.
Publicado: (2021)

Assessing Visual Outcomes: A Comparative Study of US-FDA Premarket Approval Data for Multifocal and EDOF Lens Implants in Cataract Surgery
por: Moshirfar, Majid, et al.
Publicado: (2023)

Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011
por: Rathi, Vinay K., et al.
Publicado: (2020)

Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports
por: Chang, Lee, et al.
Publicado: (2015)

Market competition among manufacturers of novel high-risk therapeutic devices receiving FDA premarket approval between 2001 and 2018
por: Rathi, Vinay K, et al.
Publicado: (2023)

Cardiovascular Safety Profile of Dapoxetine during the Premarketing Evaluation
por: Kowey, Peter R., et al.
Publicado: (2012)

Premarket Safety and Efficacy Studies for ADHD Medications in Children
por: Bourgeois, Florence T., et al.
Publicado: (2014)

United States Food and Drug Administration’s 510(k) Pathway: Drawing Implications from the Approvals of Brachytherapy Devices
por: Wang, Sophie, et al.
Publicado: (2019)

Toward Soluble 5,10-Diheterotruxenes: Synthesis and Reactivity of 5,10-Dioxatruxenes, 5,10-Dithiatruxenes, and 5,10-Diazatruxenes
por: Górski, Krzysztof, et al.
Publicado: (2020)

Left to Their Own Devices: Breakdowns in United States Medical Device Premarket Review
por: Hines, Jonas Zajac, et al.
Publicado: (2010)

Demographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017
por: Ramamoorthy, Anuradha, et al.
Publicado: (2018)

Hazardous children’s products on the Australian and US market 2011–2017: an empirical analysis of child-related product safety recalls
por: Niven, Catherine M, et al.
Publicado: (2020)

Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017
por: Zhang, Audrey D., et al.
Publicado: (2020)

US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019
por: Dhodapkar, Meera M., et al.
Publicado: (2023)

Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics
por: Varma, Tanvee, et al.
Publicado: (2021)

510. Real-world Effectiveness of Sotrovimab for COVID-19: Evidence from United States (US) Administrative Claims Data
por: Bell, Christopher F, et al.
Publicado: (2023)

Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019
por: Dhodapkar, Meera, et al.
Publicado: (2021)

Time Series Analysis of the Effectiveness and Safety of Capsule Endoscopy between the Premarketing and Postmarketing Settings: A Meta-Analysis
por: Iijima, Kazuo, et al.
Publicado: (2016)

Premarket Development Times for Innovative Vaccines––To What Extent Are the Coronavirus Disease 2019 (COVID-19) Vaccines Outliers?
por: Beall, Reed F, et al.
Publicado: (2021)

US Supercollider approved
Publicado: (1987)

Abstract QS26: A Prospective Pilot Study of Robotic-Assisted Harvest of the Latissmus Dorsi Muscle for FDA 510(K) Approval
por: Shuck, John, et al.
Publicado: (2018)

510. First Environmental Investigation of Toxigenic Clostridium difficile Strains in Texas Hospitals
por: Alam, M Jahangir, et al.
Publicado: (2018)

Association of Extreme Heat With All-Cause Mortality in the Contiguous US, 2008-2017
por: Khatana, Sameed Ahmed M., et al.
Publicado: (2022)

Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021
por: Monge, Andrea N., et al.
Publicado: (2022)

Evaluation of the Olympus AU-510 analyser
por: Farré, Carmen, et al.
Publicado: (1991)

Recall Rates of Total Knee Arthroplasty Devices Are Dependent on the FDA Approval Process
por: Pellerin, Carl, et al.
Publicado: (2020)

Premarket evaluation of medical devices: a cross-sectional analysis of clinical studies submitted to a German ethics committee
por: Sauerland, Stefan, et al.
Publicado: (2019)

Recent progress to shorten premarket evaluation and improve patient access to medical devices by the Pharmaceuticals and Medical Devices Agency of Japan
por: Handa, Nobuhiro, et al.
Publicado: (2019)

Association of expedited review programmes with postmarketing safety events of new drugs approved by the US food and drug administration between 2007 and 2017
por: Zhu, Xingyue, et al.
Publicado: (2022)

The premarket assessment of the cost-effectiveness of a predictive technology “Straticyte™” for the early detection of oral cancer: a decision analytic model
por: Khoudigian-Sinani, S., et al.
Publicado: (2017)

Characterization of US Hospital Advertising and Association With Hospital Performance, 2008-2016
por: Ndumele, Chima D., et al.
Publicado: (2021)

Highly variable trends in rates of newly diagnosed HIV cases in U.S. hotspots, 2008-2017
por: Segarra, Lorena, et al.
Publicado: (2021)

Trends and Variations in Emergency Department Use Associated With Diabetes in the US by Sociodemographic Factors, 2008-2017
por: Uppal, Tegveer S., et al.
Publicado: (2022)

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
por: Jiao, Kuo, et al.
Publicado: (2019)

Time for the US food and drug administration approval of condoms for anal intercourse
por: Nguyen, Brian T., et al.
Publicado: (2019)

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

Second Place Award Immediate versus delayed operative treatment of low-energy tibial plateau fractures
por: Ellsworth, Harold Scott, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jkqf1prorb747r1fip6bq2n7fd